BACKGROUND: The addition of cisplatin or cetuximab to radiation therapy (RT) improves outcomes in comparison with RT alone in the nonoperative management of head and neck squamous cell carcinoma (HNSCC), but limited data exist for comparing these approaches. Using Veterans Health Affairs data, this study compared the outcomes of patients treated with RT plus cisplatin or cetuximab. METHODS: Patients with stage III to IVb HNSCC who had been treated nonsurgically with RT and cisplatin or cetuximab from 2000 to 2016 within the Veterans Health Affairs system were identified. Patients were analyzed by the drug used in the first treatment cycle (intent to treat). Overall survival (OS) was compared by treatment group with Cox regression models, and propensity score (PS) methods were used to account for a treatment allocation bias. The risk of toxicities was determined, with logistic regression models fit into propensity-matched cohorts. RESULTS: A total of 4520 patients were included in the analysis with a median follow-up of 3 years: 83% received cisplatin. Cisplatin patients were younger (P < .001) and had fewer comorbidities (P < .001). In an unmatched analysis, cetuximab was associated with inferior OS (P < .001). After PS matching, cetuximab treatment remained statistically significantly associated with inferior OS (1.7 vs 4.1 years; hazard ratio, 1.61; 95% confidence interval, 1.44-1.79; P < .001). These differences remained significant across all primary HNSCC subsites and in comparison with low- and high-dose cisplatin. CONCLUSIONS: Cetuximab with RT yields inferior OS in comparison with cisplatin for the nonoperative management of stage III to IVb HNSCC. According to this study, cisplatin may be the most appropriate partner for RT in this setting.
BACKGROUND: The addition of cisplatin or cetuximab to radiation therapy (RT) improves outcomes in comparison with RT alone in the nonoperative management of head and neck squamous cell carcinoma (HNSCC), but limited data exist for comparing these approaches. Using Veterans Health Affairs data, this study compared the outcomes of patients treated with RT plus cisplatin or cetuximab. METHODS:Patients with stage III to IVb HNSCC who had been treated nonsurgically with RT and cisplatin or cetuximab from 2000 to 2016 within the Veterans Health Affairs system were identified. Patients were analyzed by the drug used in the first treatment cycle (intent to treat). Overall survival (OS) was compared by treatment group with Cox regression models, and propensity score (PS) methods were used to account for a treatment allocation bias. The risk of toxicities was determined, with logistic regression models fit into propensity-matched cohorts. RESULTS: A total of 4520 patients were included in the analysis with a median follow-up of 3 years: 83% received cisplatin. Cisplatinpatients were younger (P < .001) and had fewer comorbidities (P < .001). In an unmatched analysis, cetuximab was associated with inferior OS (P < .001). After PS matching, cetuximab treatment remained statistically significantly associated with inferior OS (1.7 vs 4.1 years; hazard ratio, 1.61; 95% confidence interval, 1.44-1.79; P < .001). These differences remained significant across all primary HNSCC subsites and in comparison with low- and high-dose cisplatin. CONCLUSIONS:Cetuximab with RT yields inferior OS in comparison with cisplatin for the nonoperative management of stage III to IVb HNSCC. According to this study, cisplatin may be the most appropriate partner for RT in this setting.
Authors: Kathleen A McGinnis; Cynthia A Brandt; Melissa Skanderson; Amy C Justice; Shahida Shahrir; Adeel A Butt; Sheldon T Brown; Matthew S Freiberg; Cynthia L Gibert; Matthew Bidwell Goetz; Joon Woo Kim; Margaret A Pisani; David Rimland; Maria C Rodriguez-Barradas; Jason J Sico; Hilary A Tindle; Kristina Crothers Journal: Nicotine Tob Res Date: 2011-09-12 Impact factor: 4.244
Authors: Carrie N Klabunde; Nancy L Keating; Arnold L Potosky; Anita Ambs; Yulei He; Mark C Hornbrook; Patricia A Ganz Journal: J Natl Cancer Inst Date: 2011-02-11 Impact factor: 13.506
Authors: Jan B Vermorken; Jan Stöhlmacher-Williams; Irina Davidenko; Lisa Licitra; Eric Winquist; Cristian Villanueva; Paolo Foa; Sylvie Rottey; Krzysztof Skladowski; Makoto Tahara; Vasant R Pai; Sandrine Faivre; Cesar R Blajman; Arlene A Forastiere; Brian N Stein; Kelly S Oliner; Zhiying Pan; Bruce A Bach Journal: Lancet Oncol Date: 2013-06-06 Impact factor: 41.316
Authors: Lawrence Koutcher; Eric Sherman; Matthew Fury; Suzanne Wolden; Zhigang Zhang; Qianxing Mo; Laschelle Stewart; Karen Schupak; Daphna Gelblum; Richard Wong; Dennis Kraus; Jatin Shah; Michael Zelefsky; David Pfister; Nancy Lee Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-13 Impact factor: 7.038
Authors: Jimmy J Caudell; Stephen M Sawrie; Sharon A Spencer; Renee A Desmond; William R Carroll; Glenn E Peters; Lisle M Nabell; Ruby F Meredith; James A Bonner Journal: Int J Radiat Oncol Biol Phys Date: 2008-03-20 Impact factor: 7.038
Authors: James A Bonner; Paul M Harari; Jordi Giralt; Roger B Cohen; Christopher U Jones; Ranjan K Sur; David Raben; Jose Baselga; Sharon A Spencer; Junming Zhu; Hagop Youssoufian; Eric K Rowinsky; K Kian Ang Journal: Lancet Oncol Date: 2009-11-10 Impact factor: 41.316
Authors: Il Seok Daniel Jeong; Huan Mo; Anthony Nguyen; Esther G Chong; Hsin Hsiang Clarence Tsai; Justin Moyers; Matthew Kim; Curtis Lacy; Vivek Shah; Eric Lau; Yi Xu; Huynh Cao Journal: Exp Hematol Oncol Date: 2020-08-05
Authors: Gregory S Weinstein; Roger Cohen; Alexander Lin; Bert W O'Malley; John Lukens; Samuel Swisher-McClure; Rabie M Shanti; Jason G Newman; Harman S Parhar; Kendall Tasche; Robert M Brody; Ara Chalian; Steven Cannady; James N Palmer; Nithin D Adappa; Michael A Kohanski; Joshua Bauml; Charu Aggarwal; Kathleen Montone; Virginia Livolsi; Zubair W Baloch; Jalal B Jalaly; Kumarasen Cooper; Karthik Rajasekaran; Laurie Loevner; Christopher Rassekh Journal: Head Neck Date: 2020-06-25 Impact factor: 3.147
Authors: Carly I Misztal; Carlos Green; Christine Mei; Rita Bhatia; Jaylou M Velez Torres; Brandon Kamrava; Seo Moon; Elizabeth Nicolli; Donald Weed; Zoukaa Sargi; Christine T Dinh Journal: Cancers (Basel) Date: 2021-11-29 Impact factor: 6.639